The global leader in AI and ML drug design with the world's first AI assisted drug discovery patent.
Designed to succeed where ATP competitive inhibitors stop working due to drug resistance.
DNA SEQ recognized by Life Sciences Review as the AI drug discovery company of the year in 2024
​
DNA SEQ is humbled to have been nominated, and, selected by an industry panel for our innovative work. DNA SEQ has discovered novel bindings sites to address drug resistance.
DNA SEQ Snapshot
DNA SEQ is a novel, small molecule drug discovery company that has patented the mechanism of cancers resistance to targeted therapies and pioneer of algorithmic approaches to creating a drug discovery platform.
​
Our awarded patents and the size of our pipeline demonstrate we are the leaders in the field of using machine learning and AI in drug design.
​
303 novel DFG INTER kinase drug candidates targeting 6 cancer indications to transform the industry. Our DFG INTER candidates have allosteric binding features.
DNA SEQ understands cancers resistance mechanism
Kinase inhibitors are cancer blocking drugs. They allow people to extend their lives after being diagnosed with certain types of cancer. Eventually cancer becomes resistant to the drugs.
​
We have identified the detailed mechanisms of resistance and can design new drugs that will address kinase mutant resistance and downstream signaling - the next revolution in cancer treatment.
We are demonstrating a new drug candidate binding to a new target of resistance that we discovered using AI and machine learning techniques.
Intellectual Property - Awarded Patents
Our patent estate presents companion diagnostic and drug design methodology assisted by machine leaning, pattern matching and artificial intelligence.
​
Novel Binding Sites For The Discovery of New Drugs: Two (2) awarded patents are structured to cover any combination where algorithms, crystal structures and genetic analysis are used as training data to find new binding sites. Specifically, it allows us to create novel molecules for validated cancer targets in six (6) cancer indications.
​
Companion Diagnostic For Optimal Treatments: Our third awarded patent is structured to cover any combination where algorithms, crystal structures and genetic analysis are used as training data to identify the best treatment for existing binding sites. Specifically, it allows us to understand how to select the optimal drug for ER positive breast cancer which affects 75% of breast cancer diagnosis.
Licensing Opportunities
Many drugs of the future that improve the lives of patients will require the use of genetic data, crystallographic structure data, and algorithms, specifically pattern matching and/or machine learning algorithms. When these are used in any combination to generate new drugs of any kind such as the use of generative AI, we are here to license our intellectual property and help you take your discoveries to the next level.
We are happy to partner with all entities who intend to use our intellectual property in order to develop drugs in the pharmaceutical space.
Janusz Sowadski Ph.D. is the founder and Chief Science Officer at DNA SEQ and was a director on the team who discovered the first 3-D structure of a kinase that led to the creation of kinase inhibitors in partnership with Novartis - the most powerful targeted drugs on the planet.
The latest discovery by Dr Sowadski of a new binding site for cancer blocking drugs has the potential to revolutionize cancer treatment once again. ​
DNA SEQ
7918 El Cajon Blvd, 420
La Mesa, CA 91942
© DNA SEQ 2, Inc 2023
Addressing drug resistance with a novel family of DFG INTER kinase inhibitors targeting numerous cancers including; lung, breast, bladder, gallbladder, melanoma and leukemia.